Novavax, Inc.

NasdaqGS:NVAX Stock Report

Market Cap: US$1.3b

Novavax Management

Management criteria checks 3/4

Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 3.33 years. total yearly compensation is $8.86M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $1.81M. The average tenure of the management team and the board of directors is 3.3 years and 5.4 years respectively.

Key information

John Jacobs

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage8.95%
CEO tenure3.3yrs
CEO ownership0.1%
Management average tenure3.3yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

NVAX: Bearish View Will Hinge On Sustained COVID Vaccination Demand

Analysts have raised their blended price targets for Novavax by about $1 per share to a range of around $7 to $8, citing updated assumptions for COVID demand, refreshed 2026 revenue and expense forecasts, and the contribution from recent partnership agreements. Analyst Commentary Recent Street research around Novavax reflects a mix of caution and tempered expectations, even as price targets move slightly higher into the mid single digit range.

NVAX: Bearish View Will Hinge On Future COVID Demand Execution

Analysts have modestly lifted their average price targets on Novavax shares, with several moving from the $6 to $7 range toward $8 as they update COVID demand assumptions and incorporate new guidance on future revenue, operating expenses, and licensing income. Analyst Commentary Recent Street research on Novavax reflects a cautious tone, even as some targets edge higher.

NVAX: Bearish Outlook Will Depend On Pfizer Royalty And COVID Demand Assumptions

Novavax's average analyst price target has edged higher by about $1, as analysts refine their COVID assumptions, update revenue and expense forecasts for future years, and factor recent partnership economics into their models. Analyst Commentary Recent Street research around Novavax points to a cautious tone, even as price targets move slightly higher.

NVAX: Cautious Outlook Will Hinge On Future Pfizer Royalty Execution

Narrative Update on Novavax The analyst price target for Novavax has increased by about $1 to a new consensus of $7, as analysts adjust their models for updated COVID demand assumptions, refreshed 2026 revenue and expense forecasts, and the impact of recent partnership and licensing agreements. Analyst Commentary Recent Street research on Novavax points to a mixed but generally cautious stance.

NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation

Analysts have lifted their average price target on Novavax to about $13.78 from roughly $13.11, citing updated COVID demand assumptions, refreshed revenue and expense forecasts, and revised P/E expectations that incorporate recent guidance and licensing agreements. Analyst Commentary Recent Street research reflects a mix of cautious optimism and ongoing concern, with several firms adjusting their price targets and underlying models around Novavax's COVID franchise, expense profile, and licensing income.

Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

Feb 27

Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified

Jan 14
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified

NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments

Novavax's analyst price target has been modestly reduced from $13.21 to $13.11 per share. This change reflects analysts' cautious optimism about the company's new licensing model, expected royalties, and commercial partnership opportunities.

Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead

The analyst price target for Novavax has been raised from $12.50 to $13.21. This reflects analyst confidence in the company’s transition to a licensing model as well as opportunities for revenue from new partnerships and technology platforms.

Global Vaccine Market Will Unlock Upside Despite Execution Risks

Novavax’s consensus price target was modestly reduced, primarily due to a slight decline in its future P/E ratio, bringing fair value down from $12.86 to $12.50. What's in the News Reports indicate that the Trump administration and Robert F.

Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth

May 20
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth

Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges

Apr 28
User avatar

Sanofi Partnership And Pipeline Programs Will Expand Future Markets

Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.

Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer

Apr 11

The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%

Apr 02
The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%

Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 12
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates

Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)

Jan 16

Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth

Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth

Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Nov 13

Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Oct 31

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

Aug 13

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Jul 26

Novavax: New Chapter, Questions Remain

Jun 20

CEO Compensation Analysis

How has John Jacobs's remuneration changed compared to Novavax's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$9mUS$793k

US$440m

Sep 30 2025n/an/a

US$342m

Jun 30 2025n/an/a

US$423m

Mar 31 2025n/an/a

US$479m

Dec 31 2024US$5mUS$753k

-US$187m

Sep 30 2024n/an/a

-US$285m

Jun 30 2024n/an/a

-US$294m

Mar 31 2024n/an/a

-US$399m

Dec 31 2023US$7mUS$663k

-US$545m

Compensation vs Market: John's total compensation ($USD8.86M) is above average for companies of similar size in the US market ($USD5.37M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Jacobs (58 yo)

3.3yrs
Tenure
US$8,856,015
Compensation

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Leadership Team

NamePositionTenureCompensationOwnership
John Jacobs
President3.3yrsUS$8.86m0.14%
$ 1.8m
James Kelly
Executive VP4.8yrsUS$2.99m0.080%
$ 1.0m
Mark Casey
Executive VP2.4yrsUS$2.81m0.055%
$ 724.2k
Elaine O'Hara
Executive VP & Chief Strategy Officer3.3yrsUS$3.69m0.083%
$ 1.1m
Richard Crowley
Executive VP & COO3.3yrsno datano data
Luis Sanay
Vice President of Investor Relationsno datano datano data
Troy Morgan
Senior VPno datano datano data
Erika Trahan
Associate Director of Investor & Public Relations8.1yrsno datano data
Ian Watkins
Executive VP & Chief Human Resources Officer2.8yrsno datano data
Silvia Taylor
Executive VP4.3yrsno datano data
Robert Walker
Executive VP and Head of Research & Development1.5yrsno data0.021%
$ 276.4k
3.3yrs
Average Tenure
59yo
Average Age

Experienced Management: NVAX's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Jacobs
President3.3yrsUS$8.86m0.14%
$ 1.8m
David Mott
Chairman of the Board of Directors5.9yrsUS$365.59k0.037%
$ 489.5k
Richard Douglas
Independent Director16.3yrsUS$364.46k0.033%
$ 436.9k
Margaret McGlynn
Independent Vice Chairman of the Board of Directors5.4yrsUS$402.28k0.016%
$ 205.7k
Gregg Alton
Independent Director5.6yrsUS$355.09k0.018%
$ 231.6k
Rachel King
Independent Director7.5yrsUS$353.09k0.015%
$ 202.5k
Richard Rodgers
Independent Director3.6yrsUS$375.45k0.017%
$ 229.1k
John Shiver
Independent Director1.2yrsUS$516.55k0.0049%
$ 63.9k
Charles Newton
Independent Director1.3yrsUS$491.95k0.0058%
$ 76.5k
5.4yrs
Average Tenure
60yo
Average Age

Experienced Board: NVAX's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/04 10:04
End of Day Share Price 2026/05/01 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novavax, Inc. is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
David LebowitzBrean Capital Historical (Janney Montgomery)
Mayank MamtaniB. Riley Securities, Inc.